Subtype
Benign Musculoskeletal Neoplasm
CI-CAN-00000516Explore in graph →
Non-malignant48 active trials5 evidence items
- NCIt
- C166356
Loading cancer entity…
Subtype
CI-CAN-00000516Explore in graph →
Clinical trials
465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01786226 | Mifepristone to Treat Uterine Fibroids | terminated | Phase 2 / Phase 3 | 220 | Mediterranea Medica S. L.OTHER | 1 | Sep 5, 2014 | clinicaltrials |
| NCT00702702 | Safety and Efficacy of Proellex in Pre-menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 56 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| Evaluating the Safety and Efficacy of Proellex® (CDB-4124) in Premenopausal Women With Symptomatic Uterine Fibroids |
| terminated |
| Phase 3 |
| 77 |
| Repros Therapeutics Inc.INDUSTRY |
| 1 |
| Aug 21, 2014 |
| clinicaltrials |
| NCT00737282 | Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids | terminated | Phase 3 | 175 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00785356 | Safety and Efficacy of Proellex in Pre-Menopausal Anemic Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 8 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT00853567 | Evaluating the Safety and Efficacy of Proellex® in Premenopausal Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 71 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT01069120 | Safety of 25 and 50 mg Proellex® in the Treatment of Women With Symptomatic Uterine Fibroids | terminated | Phase 3 | 27 | Repros Therapeutics Inc.INDUSTRY | 1 | Aug 21, 2014 | clinicaltrials |
| NCT02061657 | Impact of Misoprostol on Blood Loss In Myomectomy Operations | completed | Phase 3 | 50 | Ain Shams UniversityOTHER | 1 | Aug 12, 2014 | clinicaltrials |
| NCT00874302 | Safety and Efficacy of 25 and 50 mg Doses of Proellex® in Treating the Recurrence of Uterine Fibroid Symptoms | withdrawn | Phase 3 | 0 | Repros Therapeutics Inc.INDUSTRY | 2 | Jun 27, 2014 | clinicaltrials |
| NCT01553123 | Efficacy and Safety Study of Ulipristal Acetate in Females With Anemia Associated With Uterine Leiomyoma | withdrawn | Phase 3 | 0 | Watson PharmaceuticalsINDUSTRY | 1 | Feb 7, 2013 | clinicaltrials |
| NCT01581944 | Gonadotropin-releasing Hormone Agonist Prior to Myomectomy | completed | Phase 3 | 68 | Mt. Hope Maternity HospitalOTHER | 1 | Apr 20, 2012 | clinicaltrials |
| NCT00712595 | Mifepristone for Treatment of Uterine Fibroids(Mifemyo) | completed | Phase 2 / Phase 3 | 200 | Mediterranea Medica S. L.OTHER | 1 | Apr 23, 2009 | clinicaltrials |
| NCT00821275 | Clinical Trial of Uterine Artery Embolization for Uterine Leiomyoma | unknown | Phase 2 / Phase 3 | 900 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2009 | clinicaltrials |
| NCT00152256 | A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids | completed | Phase 3 | 239 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00152269 | Treatment of Uterine Fibroids With Asoprisnil(J867) | completed | Phase 3 | 475 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156195 | Study to Evaluate the Safety of Asoprisnil in the Treatment of Uterine Fibroids | completed | Phase 3 | 523 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156208 | Safety of Treatment of Uterine Fibroids With Asoprisnil | completed | Phase 3 | 166 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00160381 | A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids | completed | Phase 3 | 432 | AbbottINDUSTRY | 0 | May 29, 2008 | clinicaltrials |
| NCT00156156 | Study of Asoprisnil in the Treatment of Uterine Fibroids. | completed | Phase 3 | 149 | AbbottINDUSTRY | 0 | May 28, 2008 | clinicaltrials |
| NCT00017927 | A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome | completed | Phase 3 | 10 | National Institute of Dental and Craniofacial Research (NIDCR)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00100191 | Emmy Trial: Uterine Artery Embolization (UAE) Versus Hysterectomy for Uterine Fibroids | completed | Phase 3 | 120 | ZonMw: The Netherlands Organisation for Health Research and DevelopmentOTHER | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 22 days agoSource updated Sep 5, 2014source: clinicaltrials